A French cohort for assessing COVID-19 vaccine responses in specific populations
- 12 July 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (8), 1319-1321
- https://doi.org/10.1038/s41591-021-01435-1
Abstract
No abstract availableFunding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S)
This publication has 9 references indexed in Scilit:
- Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance HemodialysisClinical Journal of the American Society of Nephrology, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort studyClinical Microbiology & Infection, 2021
- Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumorsAnnals of Oncology, 2021
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort studyNephrology Dialysis Transplantation, 2021
- Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With BelataceptTransplantation, 2021
- Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipientsKidney International, 2021